Novo Nordisk
-
Communications & Technology
Wegovy®️ pill demonstrated greater weight loss than orforglipron and lower odds of stopping medication due to side effects in a new indirect comparison presented at Obesity Medicine Association 2026
Oral semaglutide 25 mg demonstrated significantly greater mean weight loss than orforglipron 36 mg in a population-adjusted indirect treatment comparison…
Read More » -
Uncategorized
Wegovy® (Semaglutide 2.4mg) an Obesity Treatment for People Living with Obesity in Oman
Muscat, Gulf Tech News : Novo Nordisk, the Danish leading global healthcare company renowned for its expertise in treating chronic…
Read More » -
Communications & Technology
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Oral semaglutide (Rybelsus®) is now the first and only oral GLP-1 RA approved for type 2 diabetes, with proven cardiovascular…
Read More » -
Uncategorized
Novo Nordisk partners with Saudi Heart Association to improve cardiovascular health in Saudi Arabia
Novo Nordisk, a leading global healthcare company, is excited to announce a new Memorandum of Understanding with the Saudi Heart…
Read More »